← Leaderboards
Yung-Chi Cheng
Yale University
$16,454,542
Attributed
$16,454,542
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2005–16$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$22,888,269 · 9
By mechanism
R01$9,089,109 · 3
P01$8,895,960 · 3
T32$2,826,044 · 1
U01$1,931,956 · 1
P30$145,200 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Peter M Glazer$37,467,142
- James Melvin Anderson$6,205,744
- Sumita Bhaduri-McIntosh$6,616,001
- Edward Chu$17,954,928
- Elijah Paintsil$5,045,527
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseBiochemicalNucleoside AnalogLaboratoriesMalignant NeoplasmsToxic EffectChemotherapy-Oncologic ProcedureProgramsStructureResearch PersonnelResistanceClinical ResearchCancer TherapyDrug ResistanceCytotoxicityPharmaceutical PreparationsTumorChinese HerbsDesignAntineoplastic AgentsGrantMethodologyHerbal MedicineClinical Efficacy
Grant awards (65)
Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy$877,772
P01 · FY2016 · CA · contact PI
Characterization of Predictive Biomarkers for the Clinical Efficacy of PHY906$364,525
P01 · FY2016 · CA · contact PI
Administration Core$69,722
P01 · FY2016 · CA · contact PI
Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy$461,274
P01 · FY2015 · CA · contact PI
Characterization of Predictive Biomarkers for the Clinical Efficacy of PHY906$188,700
P01 · FY2015 · CA · contact PI
Administration Core$36,916
P01 · FY2015 · CA · contact PI
Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy$1,246,839
P01 · FY2014 · CA · contact PI
Characterization of Predictive Biomarkers for the Clinical Efficacy of PHY906$519,643
P01 · FY2014 · CA · contact PI
Biochemical Pharmacology of Anti-HIV Compounds$409,613
R01 · FY2014 · AI · contact PI
Administration Core$98,770
P01 · FY2014 · CA · contact PI
Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy$1,214,842
P01 · FY2013 · CA · contact PI
Characterization of Predictive Biomarkers for the Clinical Efficacy of PHY906$442,058
P01 · FY2013 · CA · contact PI
Biochemical Pharmacology of Anti-HIV Compounds$385,036
R01 · FY2013 · AI · contact PI
Administration Core$105,779
P01 · FY2013 · CA · contact PI
Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy$1,292,429
P01 · FY2012 · CA · contact PI
Characterization of Predictive Biomarkers for the Clinical Efficacy of PHY906$532,600
P01 · FY2012 · CA · contact PI
Biochemical Pharmacology of Anti-HIV Compounds$409,613
R01 · FY2012 · AI · contact PI
Administration Core$103,520
P01 · FY2012 · CA · contact PI
Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy$1,340,571
P01 · FY2011 · CA · contact PI
Biochemical Pharmacology of Anti-HIV Compounds$409,613
R01 · FY2011 · AI · contact PI
Research Programs-Developmental Therapeutics$29,701
P30 · FY2011 · CA · contact PI
Nucleoside Analogs as Anticancer Compounds$702,665
U01 · FY2010 · CA · contact PI
Biochemical Pharmacology of Anti-HIV Compounds$413,750
R01 · FY2010 · AI · contact PI
Mechanism and in vivo anti-HBV study of a novel class of non-nucleoside compounds$361,647
R01 · FY2010 · AI · contact PI
Nucleoside Analogs as Anticancer Compounds$173,686
U01 · FY2010 · CA · contact PI
Research Programs-Developmental Therapeutics$33,424
P30 · FY2010 · CA · contact PI
Nucleoside Analogs as Anticancer Compounds$19,999
U01 · FY2010 · CA · contact PI
Nucleoside Analogs as Anticancer Compounds$468,303
U01 · FY2009 · CA · contact PI
Mechanism and in vivo anti-HBV study of a novel class of non-nucleoside compounds$365,300
R01 · FY2009 · AI · contact PI
Biochemical Aspects of Chemotherapy$352,079
T32 · FY2009 · CA · contact PI
Biochemical Pharmacology of Anti-HIV Compounds$315,294
R01 · FY2009 · AI · contact PI
Nucleoside Analogs as Anticancer Compounds$99,000
U01 · FY2009 · CA · contact PI
Research Programs-Developmental Therapeutics$30,252
P30 · FY2009 · CA · contact PI
Nucleoside Analogs as Anticancer Compounds$468,303
U01 · FY2008 · CA · contact PI
Mechanism and in vivo anti-HBV study of a novel class of non-nucleoside compounds$365,024
R01 · FY2008 · AI · contact PI
Biochemical Pharmacology of Anti-HIV Compounds$315,294
R01 · FY2008 · AI · contact PI
Biochemical Aspects of Chemotherapy$310,322
T32 · FY2008 · CA · contact PI
Research Programs-Developmental Therapeutics$30,252
P30 · FY2008 · CA · contact PI
Nucleoside Analogs as Anticancer Compounds$426,427
R01 · FY2007 · CA · contact PI
Mechanism and in vivo anti-HBV study of a novel class of non-nucleoside compounds$371,250
R01 · FY2007 · AI · contact PI
Biochemical Pharmacology of Anti-HIV Compounds$320,430
R01 · FY2007 · AI · contact PI
Nucleoside Analogs as Anticancer Compounds$150,000
R01 · FY2007 · CA · contact PI
Biochemical Aspects of Chemotherapy$47,537
T32 · FY2007 · CA · contact PI
Research Programs-Developmental Therapeutics$21,571
P30 · FY2007 · CA · contact PI
Biochemical Aspects of Chemotherapy$389,185
T32 · FY2006 · CA · contact PI
Biochemical Pharmacology of Anti-HIV Compounds$330,000
R01 · FY2006 · AI · contact PI
Nucleoside Analogs as Anticancer Compounds$268,558
R01 · FY2006 · CA · contact PI
Biochemical Aspects of Chemotherapy$380,218
T32 · FY2005 · CA
BIOCHEMICAL PHARMACOLOGY OF ANTI-HIV-COMPOUNDS$325,095
R01 · FY2005 · AI
Nucleoside Analogs as Anticancer Compounds$271,410
R01 · FY2005 · CA
BIOCHEMICAL PHARMACOLOGY OF ANTI-HIV-COMPOUNDS$325,095
R01 · FY2004 · AI
BIOCHEMICAL ASPECTS OF CHEMOTHERAPY$315,385
T32 · FY2004 · CA
Nucleoside Analogs as Anticancer Compounds$271,410
R01 · FY2004 · CA
BIOCHEMICAL PHARMACOLOGY OF ANTI-HIV-COMPOUNDS$325,095
R01 · FY2003 · AI
Nucleoside Analogs as Anticancer Compounds$271,410
R01 · FY2003 · CA
BIOCHEMICAL ASPECTS OF CHEMOTHERAPY$198,040
T32 · FY2003 · CA
BIOCHEMICAL PHARMACOLOGY OF ANTI-HIV-COMPOUNDS$325,095
R01 · FY2002 · AI
BIOCHEMICAL ASPECTS OF CHEMOTHERAPY$306,892
T32 · FY2002 · CA
Nucleoside Analogs as Anticancer Compounds$271,410
R01 · FY2002 · CA
BIOCHEMICAL PHARMACOLOGY OF ANTI-HIV-COMPOUNDS$308,745
R01 · FY2001 · AI
Nucleoside Analogs as Anticancer Compounds$271,410
R01 · FY2001 · CA
BIOCHEMICAL ASPECTS OF CHEMOTHERAPY$260,648
T32 · FY2001 · CA
BIOCHEMICAL PHARMACOLOGY OF ANTIHIV-1 COMPOUNDS$269,010
R01 · FY2000 · AI
BIOCHEMICAL ASPECTS OF CHEMOTHERAPY$265,738
T32 · FY2000 · CA
NUCLEOSIDE ANALOGS AS ANTICANCER COMPOUNDS$237,075
R01 · FY2000 · CA